Introduction {#s1}
============

Cancer is a chronic disease that severely affects the lives and health of people in most countries and regions worldwide. The World Health Organization\'s International Agency for Research on Cancer recently published cancer statistics indicating that: 14.1 million new cancer cases, 8.4 million deaths occurred in 2012 worldwide (Torre et al., [@B54]). There is a growing body of evidence showing that carcinogenic effects are complex processes involving multiple environmental and genetic factors, although the cause of carcinogenic effects has not yet been completely clarified.

Micro-ribonucleic acids (miRNAs) are \~19- to 24-nucleotide RNA molecules that can regulate the expression of other genes in eukaryotes (Bartel, [@B7]). A growing number of studies have shown that miRNAs play an important role in regulating a variety of cellular functions. Impairment of miRNA expression is usually associated with various diseases. MicroRNAs play an important regulatory role in tumorigenesis through the regulation of cancer-related target gene expression and pathways. A variety of evidence suggests that miRNAs can participate in immune responses; inflammatory responses; infections; and cellular metabolism, growth and migration (Jovanovic and Hengartner, [@B25]).

MiR-499 is one of the microRNAs that plays important posttranscriptional regulatory roles by modulating several genes and signaling pathways, particularly under hypoxic-ischemic conditions such as in cancer and myocardial infarction (Wilson et al., [@B64]; Ando et al., [@B5]). Liu et al. ([@B34]) indicated that miR-499 could promote metastasis of colorectal cancer cells by targeting FOXO4 and PDCD4, and miR-499 might be regarded as a new potential therapeutic target for colorectal cancer. Li et al. also found that miR-499 functions as a tumor suppressor in non-small cell lung cancer by targeting VAV3 (Li M. et al., [@B31]). MiR-499 is related to several signaling pathways such as wnt/β-catenin signal pathway (Zhang et al., [@B73]). A study by Wang et al. ([@B59]) suggested that downregulation of the miR-499-5p level impaired the PI3K/AKT/GSK signaling pathway and glycogen synthesis by targeting PTEN. Ando et al. ([@B5]) reported that the tumor-targeted delivery of miR-499 was very effective so as to implement cancer therapy. Okamoto et al. ([@B40]) found that APRPG-miR-499 may be a combination therapeutic agent for cancer treatment.

Single nucleotide genetic variants that occur in miRNAs may influence microRNA biogenesis, stability of mature microRNA molecules, efficiency of target gene regulation, as well as specificity of targets, which may involve developing susceptibility to cancer, thus, miRNAs play an important role in the occurrence and development of malignant tumors (Nikolic et al., [@B39]).

Accumulated evidence suggests that miR-499 rs3746444 is associated with the susceptibility to many cancers. Zhang et al. ([@B71]) reported that the miR-499 rs3746444 polymorphism is associated with the risk of oral squamous cell cancer in Chinese individuals. Hashemi et al. ([@B19]) found that the rs3746444 polymorphism in miR-499 can increase the risk of prostate cancer in an Iranian population. The rs3746444 single nucleotide polymorphism was also found to be clearly associated with lung cancer (Li D. et al., [@B29]). Wang et al. ([@B60]) found that miR-499A\>G polymorphism is associated with an increased risk of hepatocellular carcinoma in Chinese individuals. However, Zhang et al. ([@B72]) suggested that there is no association between miR-499 variant and the risk of hepatocellular carcinoma in the co-dominant, dominant, and recessive models. These two articles similarly focus on hepatocellular carcinoma, but it led to very different results. In a Greek population, a case--control study demonstrated that the rs3746444 polymorphism in miR-499 is not associated with colorectal cancer (Dikaiakos et al., [@B13]). For this gene locus, many investigators have conducted exploratory studies and also obtained a number of different results, different outcomes for different types of cancer, and even the same cancer may have different results. The association between miR-499 rs3746444 and the susceptibility to cancer has not yet reached a clear consensus.

Now that increasingly more and more researchers have studied the association between cancer risk and miR-499 polymorphism, it is necessary to integrate these results to further explore the relationship between the miR-499 polymorphism and cancer risk of different systems at the level of statistics.

Materials and methods {#s2}
=====================

Literature retrieval
--------------------

We retrieved articles from PubMed and EMBASE using the following terms "microRNA-499 or miR-499 or rs3746444" and "cancer or carcinoma" published prior to January 10, 2018. In order to be more comprehensive and rigorous, we searched for the documents mentioned in the original article and the references to find more qualified article. There is no language restriction on the retrieved literature.

Study selection and data extraction
-----------------------------------

All incorporated literature must clearly meet the following three criteria: (a) evaluation of the miR-499 rs3746444 polymorphism and cancer risks; (b) a case-control study; and (c) sufficient published data for the computation of odds ratios (ORs) with 95% confidence intervals (CIs). The exclusion criteria were as follows: (a) Animal studies; (b) not for cancer research; (c) meta-analyses or review articles; Two reviewers independently extract data. If the opinion is inconsistent, the third review will join the in-depth discussion to determine whether the article should be obtained. The main contents of extracted information included the name of first author, publication date, country of origin, ethnicity, cancer type, characteristics of controls, the number of cases and controls with miR-499 T/C genotypes and the total number of cases and controls. According to the source of the control, we defined controls as population-based and hospital-based.

Statistical methods
-------------------

We firstly calculated the value of Hardy-Weinberg equilibrium (HWE) of the control groups by using the chi-square goodness-of-fit test including all retrieved literature (a *P* \< 0.05 was regarded representative of a departure from HWE). ORs corresponding to 95% CI was used to estimate the strength of association between miR-499 rs3746444 T/C and different cancer risk. The pooled ORs were conducted for five genetic comparison models: allelic model (C vs. T), homozygote comparison (CC vs. TT), heterozygote comparison (TC vs. TT), recessive model (CC vs. TC/TT), dominant model (CC/TC vs. TT). Heterogeneity among retrieved literature was used to evaluate by *I*^2^ test and Q test (a significance level of *P* \< 0.05 and/or *I*^2^ ≥ 50%). If there was obvious heterogeneity (*I*^2^ ≥ 50%), we conducted with a random-effects model (DerSimonian and Laird), otherwise, we analyzed with a fixed-effects model (Mantel--Haenszel) to obtain summary associations between miR-499 rs3746444 T/C and different cancer risk. Then subgroup analysis was done by ethnicity, different systems, source of control, and type of tumor, HWE in controls (yes/no). Sensitivity analyses were used to evaluate the stabilization of the results. Potential effect of publication bias of literatures was estimated by funnel plots and the Egger\'s test. A *P* \< 0.05 or the unsymmetrical funnel plot were regarded as statistically significant. Statistical analysis was done by Stata11.0 Software. All the *P*-values are two-sided.

Results {#s3}
=======

Study characteristics
---------------------

We first obtained 219 articles by using our specified search terms (Figure [1](#F1){ref-type="fig"}). After reading the titles and the abstracts, 83 articles were excluded. To meet the screening criteria set out earlier, we also excluded an additional 74 articles, including 54 meta-analyses, 9 articles with missing data, and 11 articles concerning prognosis. Finally, a total of 62 articles (65 studies) consisting of 23,762 cases and 28,694 controls were used for further analysis. Of the 65 studies, sample sizes ranged from 175 to 3,585, and publication year ranged from 2009 to 2017. In total, there were 2 acute lymphoblastic leukemia studies (Gutierrez-Camino et al., [@B16]; Hasani et al., [@B18]), 10 breast cancer studies (Hu et al., [@B23]; Catucci et al., [@B9]; Alshatwi et al., [@B4]; Bansal et al., [@B6]; Omrani et al., [@B42]; He et al., [@B20]; Qi et al., [@B46]; Dai et al., [@B11]; Afsharzadeh et al., [@B1]), 3 bladder cancer studies (Mittal et al., [@B38]; Deng et al., [@B12]; Wang et al., [@B58]), 5 colorectal cancer studies (Min et al., [@B37]; Vinci et al., [@B56]; Hu et al., [@B22]; Dikaiakos et al., [@B13]; Ying et al., [@B69]), 2 cervical squamous cell carcinoma studies (Zhou et al., [@B75]; Srivastava et al., [@B52]), 3 esophageal cancer studies (Umar et al., [@B55]; Wei et al., [@B62]; Shen et al., [@B50]), 7 gastric cancer studies (Okubo et al., [@B41]; Ahn et al., [@B2]; Wu et al., [@B65]; Pu et al., [@B44]; Cai et al., [@B8]; Poltronieri-Oliveira et al., [@B43]; Rogoveanu et al., [@B48]), 17 hepatocellular carcinoma studies (Akkiz et al., [@B3]; Kim et al., [@B26]; Xiang et al., [@B66]; Zhou et al., [@B76], [@B74]; Shan et al., [@B49]; Zou and Zhao, [@B78]; Chu et al., [@B10]; Hao et al., [@B17]; Kou et al., [@B27]; Ma et al., [@B36]; Qi et al., [@B45]; Wang et al., [@B60]; Li D. et al., [@B28]; Li X. et al., [@B32]; Yan et al., [@B68]; Zhang et al., [@B72]), 4 lung cancer studies (Tian et al., [@B53]; Vinci et al., [@B57]; Li D. et al., [@B29]), 2 oral squamous cell cancer studies (Hou et al., [@B21]; Zhang et al., [@B71]), 3 prostate cancer (George et al., [@B15]; Nikolic et al., [@B39]; Hashemi et al., [@B19]), and other cancer studies \[1 cervical squamous cell carcinoma study (Zhou et al., [@B75]), 1 endometrial cancer study (Liu et al., [@B33]), 1 gallbladder cancer study (Srivastava et al., [@B51]), 1 ovarian cancer study (Liu et al., [@B33]), 1 nasopharyngeal carcinoma study (Qiu et al., [@B47]), 1 renal cell cancer study (Du et al., [@B14]), 1 cell carcinoma of head and neck study (Liu et al., [@B35])\]. There were 22 studies on Caucasians and 43 studies on Asians. Table [1](#T1){ref-type="table"} indicates the main characteristics of each study included in this meta-analysis. We separated these studies into several categories, such as cancers of the respiratory system (8 studies), digestive system (33 studies), urinary system (7 studies), gynecological system (14 studies), and lymphatic and hematopoietic system (2 studies).

###### 

Characteristics of all the studies in the meta-analysis.

  **Authors**            **Year**   **Country**    **Ethnicity**   **Cancer type**   **Study design**   **Number cases/controls**   **Cases**   **Controls**                            
  ---------------------- ---------- -------------- --------------- ----------------- ------------------ --------------------------- ----------- -------------- ----- ------ ----- ----- ----------
  Zhang                  2017       China          Asian           OSCC              HB                 340/340                     191         118            31    217    111   12    0.633
  Srivastava             2017       India          Caucasian       CSCC              PB                 184/164                     26          78             80    54     76    34    0.448
  Rogoveanu              2017       Romania        Caucasian       GC                HB                 142/288                     80          58             4     173    107   8     0.072
  Poltronieri-Oliveira   2017       Brazil         Caucasian       GC                HB                 150/239                     97          48             5     143    90    6     0.060
  Afsharzadeh            2017       Iran           Caucasian       BC                HB                 100/150                     63          33             4     66     65    19    0.633
  Hashemi                2016       Iran           Caucasian       PC                HB                 169/182                     62          82             25    85     64    33    0.002
  Li                     2016       China          Asian           LC                PB                 500/500                     316         149            35    350    130   20    0.079
  Li                     2016       China          Asian           LC                PB                 700/700                     461         195            44    500    172   28    0.009
  Zhang                  2016       China          Asian           HCC               HB                 175/302                     115         49             11    197    87    18    0.052
  Shen                   2016       China          Asian           ESCC              PB                 1400/2185                   1019        352            29    1646   492   47    0.155
  Ying                   2016       China          Asian           CRC               PB                 1350/1075                   872         336            142   713    245   117   \< 0.001
  Wang                   2016       China          Asian           BLC               PB                 283/283                     190         70             23    203    70    10    0.206
  Dai                    2016       China          Asian           BC                HB                 560/583                     407         135            18    463    109   11    0.131
  Nikoli                 2015       Serbia         Caucasian       PC                PB                 355/307                     190         147            18    180    110   17    0.971
  Cai                    2015       China          Asian           GC                PB                 363/969                     261         89             13    765    179   25    \< 0.001
  Li                     2015       China          Asian           HCC               PB                 266/250                     150         92             24    166    83    17    0.14
  Liu                    2015       China          Asian           EC                PB                 141/100                     123         18             0     77     23    0     0.194
  Liu                    2015       China          Asian           OC                PB                 75/100                      58          17             0     77     23    0     0.194
  Qi                     2015       China          Asian           BC                HB                 321/290                     152         117            52    141    112   37    0.053
  He                     2015       China          Asian           BC                HB                 450/450                     184         177            89    203    188   59    0.143
  Deng                   2015       China          Asian           BLC               PB                 159/298                     107         45             7     216    68    14    0.007
  Dikaiakos              2015       Greece         Caucasian       CRC               HB                 157/299                     85          64             8     182    99    18    0.361
  Li                     2015       China          Asian           HCC               HB                 184/184                     117         43             24    128    39    17    \< 0.001
  Qiu                    2015       China          Asian           NPC               PB                 906/1072                    614         243            49    750    284   38    0.089
  Yan                    2015       China          Asian           HCC               PB                 274/328                     147         98             29    188    112   28    0.06
  Hou                    2015       China          Asian           OSCC              HB                 512/668                     394         109            9     464    192   12    0.119
  Wang                   2014       China          Asian           HCC               HB                 152/304                     98          32             22    218    62    24    \< 0.001
  Bansal                 2014       India          Caucasian       BC                PB                 121/164                     80          30             11    106    43    15    0.002
  Omrani                 2014       Iran           Caucasian       BC                PB                 236/203                     131         44             61    130    48    25    \< 0.001
  Du                     2014       China          Asian           RCC               HB                 354/362                     251         94             9     255    96    11    0.594
  Hasani                 2014       Iran           Caucasian       ALL               HB                 75/115                      35          28             12    61     42    12    0.249
  Qi                     2014       China          Asian           HCC               PB                 314/406                     195         117            2     301    101   4     0.157
  Ma                     2014       China          Asian           HCC               PB                 984/991                     724         241            19    765    179   25    \< 0.001
  Chu                    2014       China          Asian           HCC               HB                 188/337                     119         60             9     281    55    1     0.321
  Gutierrezcamino        2014       Spain          Caucasian       ALL               PB                 200/347                     138         56             6     206    117   24    0.194
  Hu                     2014       China          Asian           CRC               HB                 211/373                     157         49             5     282    81    10    0.162
  Kou                    2014       China          Asian           HCC               HB                 271/532                     210         49             12    391    110   31    \< 0.001
  Hao                    2014       China          Asian           HCC               HB                 235/281                     160         51             24    204    61    16    \< 0.001
  Zhou                   2014       China          Asian           HCC               HB                 266/281                     184         59             23    204    61    16    \< 0.001
  Zou                    2013       China          Asian           HCC               HB                 185/185                     136         44             5     123    48    14    0.005
  Wu                     2013       China          Asian           GC                HB                 200/211                     149         47             4     166    42    3     0.854
  Wei                    2013       China          Asian           ESCC              HB                 358/376                     291         60             7     289    76    11    0.036
  Vinci                  2013       Italy          Caucasian       CRC               HB                 160/178                     93          32             35    105    56    17    0.026
  Shan                   2013       China          Asian           HCC               HB                 172/185                     128         37             7     123    48    14    0.005
  Umar                   2013       India          Caucasian       ESCC              PB                 289/309                     155         122            12    149    140   20    0.087
  Pu                     2013       China          Asian           GC                HB                 196/504                     141         50             5     366    121   17    0.082
  Ahn                    2013       Korea          Asian           GC                HB                 461/447                     323         123            15    299    134   14    0.829
  Zhou                   2012       China          Asian           HCC               PB                 186/483                     141         41             4     371    100   12    0.1
  Xiang                  2012       China          Asian           HCC               HB                 100/100                     36          40             24    52     35    13    0.081
  Min                    2012       Korea          Asian           CRC               PB                 446/502                     292         142            12    334    154   14    0.453
  Kim                    2012       Korea          Asian           HCC               PB                 159/201                     109         47             3     120    74    7     0.278
  Chu                    2012       China          Asian           OSCC              HB                 470/425                     339         119            12    356    66    3     0.975
  Alshatwi               2012       Saudi Arabia   Caucasian       BC                HB                 100/100                     30          62             8     45     40    15    0.227
  Zhou                   2011       China          Asian           CSCC              PB                 226/309                     134         84             8     223    71    15    0.005
  Vinci                  2011       Italy          Caucasian       LC                HB                 101/129                     53          41             7     70     48    11    0.503
  Mittal                 2011       India          Caucasian       BLC               PB                 212/250                     95          92             25    121    94    35    0.02
  Akkiz                  2011       Turkey         Caucasian       HCC               PB                 222/222                     45          87             90    47     93    82    0.036
  George                 2011       India          Caucasian       PC                PB                 159/230                     48          98             13    104    92    34    0.073
  Srivastava             2010       India          Caucasian       GBC               PB                 230/230                     112         97             21    121    94    15    0.566
  Okubo                  2010       Japan          Asian           GC                HB                 552/697                     364         151            37    466    198   33    0.048
  Catucci                2010       Italy          Caucasian       BC                PB                 756/1242                    414         295            47    704    452   86    0.25
  Catucci                2010       Germany        Caucasian       BC                PB                 823/925                     536         250            37    601    290   34    0.893
  Liu                    2010       USA            Caucasian       SCCHN             HB                 1109/1130                   745         309            55    710    366   54    0.441
  Tian                   2009       China          Asian           LC                PB                 1058/1035                   781         253            24    755    254   26    0.404
  Hu                     2009       China          Asian           BC                PB                 1009/1093                   707         258            44    816    248   29    0.057
  Chu                    2014       China          Asian           HCC               HB                 188/337                     119         60             9     281    55    1     0.321

*ALL, acute lymphoblastic leukemia; BC, breast cancer; BLC, bladder cancer; CRC, colorectal cancer; CSCC, cervical squamous cell carcinoma; EC, endometrial cancer; ESCC, esophageal cancer; GC, gastric cancer; GBC, gallbladder cancer; HCC, hepatocellular carcinoma; LC, lung cancer; NPC, nasopharyngeal carcinoma; OC, ovarian cancer; OSCC, oral squamous cell cancer; PC, prostate cancer; RCC, renal cell cancer; SCCHN, cell carcinoma of head and neck*.

![Flow chart of the study selection process.](fphys-09-00737-g0001){#F1}

Meta-analysis results
---------------------

As is shown in Table [2](#T2){ref-type="table"}, the main analyses performed included association and heterogeneity tests. Among all studies, we found significant associations between miR-499 rs3746444 polymorphism and cancer susceptibility in five kinds of genetic models. (CC vs. TT: OR = 1.227, 95% CI = 1.084--1.388, *P* = 0.001; TC vs. TT: OR = 1.108, 95% CI = 1.035--1.186, *P* = 0.003; CC+TC vs. TT: OR = 1.136, 95% CI = 1.061--1.216, *P* \< 0.001; CC vs. TC+TT: OR = 1.177, 95% CI = 1.045--1.326, *P* = 0.007; C vs. T: OR = 1.126, 95% CI = 1.059--1.197, *P* \< 0.001).

###### 

Pooled ORs and 95% CIs for microRNA-499 polymorphism of stratified meta-analysis.

  **Subgroup**                         **Genotype**   **No**.   **Test of association**   **Test of heterogeneity**                                         
  ------------------------------------ -------------- --------- ------------------------- --------------------------- ------------- --- -------- ---------- ------
  TOTAL                                CC vs. TT      65        1.227 (1.084, 1.388)      3.25                        **0.001**     R   126.21   \< 0.001   50.9
                                       TC vs. TT      65        1.108 (1.035, 1.186)      2.97                        **0.003**     R   163.27   \< 0.001   60.8
                                       CC+TC vs. TT   65        1.136 (1.061, 1.216)      3.66                        \<**0.001**   R   186.38   \< 0.001   65.7
                                       CC vs. TC+TT   65        1.177 (1.045, 1.326)      2.68                        **0.007**     R   124.88   \< 0.001   50.4
                                       C vs. T        65        1.126 (1.059, 1.197)      3.82                        \<**0.001**   R   217.32   \< 0.001   70.6
  Respiratory system                   CC vs. TT      8         1.575 (1.268, 1.955)      4.11                        \<**0.001**   F   13.03    0.071      46.3
                                       TC vs. TT      8         1.118 (0.923, 1.354)      1.14                        0.253         R   27.04    \< 0.001   74.1
                                       CC+TC vs. TT   8         1.171 (0.956, 1.435)      1.52                        0.128         R   33.52    \< 0.001   79.1
                                       CC vs. TC+TT   8         1.527 (1.232, 1.892)      3.86                        \<**0.001**   F   11.10    0.134      37.0
                                       C vs. T        8         1.188 (0.987, 1.429)      1.82                        0.069         R   37.55    \< 0.001   81.4
  Digestive system                     CC vs. TT      33        1.153 (1.027,1.295)       2.41                        **0.016**     F   48.54    0.031      34.1
                                       TC vs. TT      33        1.109 (1.046,1.176)       3.47                        **0.001**     F   63.88    0.001      49.9
                                       CC+TC vs. TT   33        1.112 (1.018,1.216)       2.34                        **0.019**     R   74.47    \< 0.001   57.0
                                       CC vs. TC+TT   33        1.137 (1.016,1.272)       2.24                        **0.025**     R   46.30    0.049      30.9
                                       C vs. T        33        1.112 (1.025,1.206)       2.55                        **0.011**     R   89.63    \< 0.001   64.3
  Urinary system                       CC vs. TT      7         1.068 (0.818,1.394)       0.49                        0.627         F   5.64     0.465      0.0
                                       TC vs. TT      7         1.307 (1.130,1.512)       3.61                        \<**0.001**   F   9.57     0.072      48.1
                                       CC+TC vs. TT   7         1.259 (1.097,1.446)       3.27                        **0.001**     F   6.97     0.324      13.9
                                       CC vs. TC+TT   7         0.888 (0.689,1.144)       0.92                        0.358         F   9.47     0.149      36.6
                                       C vs. T        7         1.132 (1.014,1.264)       2.21                        **0.027**     F   3.33     0.767      0.0
  Gynecological system                 CC vs. TT      14        1.369 (0.990, 1.892)      1.90                        0.057         R   40.28    \< 0.001   72.7
                                       TC vs. TT      14        1.122 (0.951, 1.324)      1.36                        0.174         R   39.02    \< 0.001   66.7
                                       CC+TC vs. TT   14        1.180 (0.995, 1.400)      1.91                        0.057         R   47.41    \< 0.001   72.6
                                       CC vs. TC+TT   14        1.279 (0.950, 1.724)      1.62                        0.105         R   37.62    \< 0.001   70.8
                                       C vs. T        14        1.169 (1.002, 1.364)      1.99                        **0.047**     R   60.95    \< 0.001   78.7
  Lymphatic and hematopoietic system   CC vs. TT      2         0.809 (0.179,3.662)       0.28                        0.783         R   5.50     0.019      81.8
                                       TC vs. TT      2         0.813 (0.586,1.128)       1.24                        0.216         F   1.65     0.198      39.5
                                       CC+TC vs. TT   2         0.885 (0.458,1.710)       0.36                        0.716         R   3.70     0.055      72.9
                                       CC vs. TC+TT   2         0.832 (0.218,3.180)       0.27                        0.788         R   4.58     0.032      78.2
                                       C vs. T        2         0.914 (0.462,1.808)       0.26                        0.796         R   6.36     0.012      84.3
  Caucasian                            CC vs. TT      22        1.110 (0.874,1.410)       0.85                        0.394         R   57.01    \< 0.001   63.2
                                       TC vs. TT      22        1.082(0.942,1.242)        1.12                        0.263         R   60.00    \< 0.001   65.0
                                       CC+TC vs. TT   22        1.106 (0.968,1.263)       1.48                        0.139         R   63.40    \< 0.001   66.9
                                       CC vs. TC+TT   22        1.038 (0.823,1.310)       0.32                        0.751         R   60.65    \< 0.001   65.4
                                       C vs. T        22        1.077 (0.963,1.205)       1.30                        0.195         R   75.17    \< 0.001   72.1
  Asian                                CC vs. TT      43        1.301 (1.180, 1.434)      5.28                        \<**0.001**   F   67.39    0.004      40.6
                                       TC vs. TT      43        1.123 (1.040, 1.213)      2.97                        **0.003**     R   99.45    \< 0.001   57.8
                                       CC+TC vs. TT   43        1.152 (1.065, 1.247)      3.52                        \<**0.001**   R   118.06   \< 0.001   64.4
                                       CC vs. TC+TT   43        1.267 (1.151, 1.394)      4.83                        \<**0.001**   F   61.94    0.015      35.4
                                       C vs. T        43        1.151 (1.072, 1.237)      3.85                        \<**0.001**   R   135.59   \< 0.001   69.0
  PB                                   CC vs. TT      32        1.216 (1.032,1.434)       2.33                        **0.020**     R   62.80    \< 0.001   53.8
                                       TC vs. TT      32        1.152 (1.063,1.249)       3.45                        **0.001**     R   66.88    \< 0.001   53.7
                                       CC+TC vs. TT   32        1.169 (1.079,1.267)       3.81                        \<**0.001**   R   74.54    \< 0.001   58.4
                                       CC vs. TC+TT   32        1.151 (0.983,1.348)       1.74                        0.081         R   62.46    \< 0.001   53.6
                                       C vs. T        32        1.146 (1.066,1.231)       3.69                        \<**0.001**   R   88.23    \< 0.001   64.9
  HB                                   CC vs. TT      33        1.283 (1.135, 1.450)      3.98                        \<**0.001**   F   63.03    0.001      49.2
                                       TC vs. TT      33        1.065 (0.952, 1.192)      1.11                        0.269         R   89.38    \< 0.001   64.2
                                       CC+TC vs. TT   33        1.104 (0.984, 1.239)      1.68                        0.093         R   107.48   \< 0.001   70.2
                                       CC vs. TC+TT   33        1.262 (1.120, 1.422)      3.82                        \<**0.001**   F   61.52    0.001      48.0
                                       C vs. T        33        1.108 (0.999, 1.229)      1.93                        0.053         R   127.45   \< 0.001   74.9
  HWE YES                              CC vs. TT      44        1.241 (1.054,1.461)       2.59                        **0.010**     R   87.07    \< 0.001   52.9
                                       TC vs. TT      44        1.109 (1.019,1.208)       2.39                        **0.017**     R   123.62   \< 0.001   65.2
                                       CC+TC vs. TT   44        1.133 (1.037,1.238)       2.76                        **0.006**     R   148.27   \< 0.001   71.0
                                       CC vs. TC+TT   44        1.230 (1.115,1.356)       4.14                        \<**0.001**   F   80.13    \< 0.001   48.8
                                       C vs. T        44        1.120 (1.036,1.211)       2.84                        **0.004**     R   166.32   \< 0.001   74.1
  HWE NO                               CC vs. TT      21        1.203 (1.203,1.364)       2.89                        **0.004**     F   38.85    0.007      48.5
                                       TC vs. TT      21        1.139 (1.056,1.229)       3.38                        **0.001**     F   38.35    0.008      47.9
                                       CC+TC vs. TT   21        1.158 (1.080,1.241)       4.14                        \<**0.001**   F   36.77    0.012      45.6
                                       CC vs. TC+TT   21        1.163 (0.956,1.415)       1.51                        0.132         R   44.40    0.001      55.0
                                       C vs. T        21        1.141 (1.037,1.254)       2.72                        **0.007**     R   50.05    \< 0.001   60.0
  ALL                                  CC vs. TT      2         0.809 (0.179,3.662)       0.28                        0.783         R   5.50     0.019      81.8
                                       TC vs. TT      2         0.813 (0.586,1.128)       1.24                        0.216         F   1.65     0.198      39.5
                                       CC+TC vs. TT   2         0.885 (0.458,1.710)       0.36                        0.716         R   3.70     0.055      72.9
                                       CC vs. TC+TT   2         0.832 (0.218,3.180)       0.27                        0.788         R   4.58     0.032      78.2
                                       C vs. T        2         0.914 (0.462,1.808)       0.26                        0.796         R   6.36     0.012      84.3
  BC                                   CC vs. TT      10        1.275 (0.956,1.700)       1.65                        0.098         R   23.22    0.006      61.2
                                       TC vs. TT      10        1.077 (0.930,1.246)       0.99                        0.322         R   19.44    0.022      53.7
                                       CC+TC vs. TT   10        1.130 (0.974,1.311)       1.61                        0.107         R   23.17    0.006      61.1
                                       CC vs. TC+TT   10        1.230 (0.918,1.646)       1.39                        0.165         R   25.37    0.033      64.5
                                       C vs. T        10        1.132 (0.982,1.304)       1.71                        0.087         R   32.71    \< 0.001   72.5
  BLC                                  CC vs. TT      3         1.292 (0.684,2.442)       0.79                        0.429         R   4.33     0.115      53.8
                                       TC vs. TT      3         1.200 (0.950,1.517)       1.53                        0.126         F   0.61     0.737      0.0
                                       CC+TC vs. TT   3         1.220 (0.981,1.519)       1.79                        0.074         F   0.15     0.930      0.0
                                       CC vs. TC+TT   3         1.208 (0.607,2.406)       0.54                        0.591         R   5.28     0.071      62.1
                                       C vs. T        3         1.174 (0.984,1.401)       1.78                        0.075         F   1.78     0.410      0.0
  CRC                                  CC vs. TT      5         1.094 (0.879,1.362)       0.81                        0.420         F   6.10     0.192      34.4
                                       TC vs. TT      5         1.085 (0.950,1.240)       1.20                        0.231         F   5.43     0.246      26.3
                                       CC+TC vs. TT   5         1.089 (0.964,1.230)       1.38                        0.169         F   1.06     0.900      0.0
                                       CC vs. TC+TT   5         1.161 (0.747,1.805)       0.66                        0.506         R   9.25     0.055      56.8
                                       C vs. T        5         1.078 (0.975,1.191)       1.47                        0.143         F   2.84     0.586      0.0
  CSCC                                 CC vs. TT      2         2.148 (0.404,11.415)      0.90                        0.370         R   9.62     0.002      89.6
                                       TC vs. TT      2         2.070 (1.472,2.771)       4.36                        \<**0.001**   F   0.05     0.819      0.0
                                       CC+TC vs. TT   2         2.221 (1.346,3.665)       3.12                        **0.002**     R   2.49     0.114      59.9
                                       CC vs. TC+TT   2         1.529 (0.386,6.057)       0.60                        0.546         R   7.66     0.006      86.9
                                       C vs. T        2         1.845 (1.158,2.940)       2.58                        **0.010**     R   4.62     0.032      78.3
  ESCC                                 CC vs. TT      3         0.815 (0.564,1.177)       1.09                        0.275         F   1.79     0.408      0.0
                                       TC vs. TT      3         0.950 (0.725,1.245)       0.37                        0.712         R   5.53     0.063      63.8
                                       CC+TC vs. TT   3         0.921 (0.691,1.226)       0.57                        0.572         R   6.66     0.036      70.0
                                       CC vs. TC+TT   3         0.818 (0.568,1.178)       1.08                        0.280         F   1.16     0.560      0.0
                                       C vs. T        3         0.915 (0.712,1.174)       0.70                        0.483         R   6.99     0.030      71.4
  GC                                   CC vs. TT      7         1.251 (0.925,1.692)       1.45                        0.146         F   2.01     0.919      0.0
                                       TC vs. TT      7         1.052 (0.926,1.194)       0.77                        0.439         F   9.73     0.136      38.4
                                       CC+TC vs. TT   7         1.074 (0.951,1.214)       1.16                        0.248         F   9.59     0.143      37.5
                                       CC vs. TC+TT   7         1.243 (0.922,1.676)       1.43                        0.154         F   1.83     0.935      0.0
                                       C vs. T        7         1.083 (0.975,1.203)       1.49                        0.135         F   8.63     0.195      30.5
  HCC                                  CC vs. TT      17        1.197 (0.902,1.579)       1.28                        0.202         R   33.65    0.006      52.5
                                       TC vs. TT      17        1.146 (0.981,1.339)       1.72                        0.085         R   39.67    0.001      59.7
                                       CC+TC vs. TT   17        1.178 (0.998,1.390)       1.94                        0.053         R   52.18    \< 0.001   69.3
                                       CC vs. TC+TT   17        1.206 (1.022,1.423)       2.21                        **0.027**     F   29.51    0.021      45.8
                                       C vs. T        17        1.169 (1.005,1.360)       2.02                        **0.043**     R   64.61    \< 0.001   75.2
  LC                                   CC vs. TT      4         1.392 (1.039, 1.866)      2.21                        **0.027**     F   5.29     0.152      43.3
                                       TC vs. TT      4         1.110 (0.974, 1.266)      1.56                        0.118         F   3.50     0.320      14.4
                                       CC+TC vs. TT   4         1.161 (0.959, 1.406)      1.53                        0.126         R   6.13     0.105      51.1
                                       CC vs. TC+TT   4         1.335 (0.999, 1.785)      1.95                        0.051         F   4.60     0.203      34.8
                                       C vs. T        4         1.157 (0.951, 1.407)      1.46                        0.145         R   8.79     0.032      65.9
  OSCC                                 CC vs. TT      3         2.116 (0.857,5.229)       1.62                        0.104         R   5.80     0.055      65.5
                                       TC vs. TT      3         1.145 (0.623,2.103)       0.44                        0.663         R   23.24    \< 0.001   91.4
                                       CC+TC vs. TT   3         1.275 (0.648,2.316)       0.62                        0.533         R   27.31    \< 0.001   92.7
                                       CC vs. TC+TT   3         2.051 (0.951,4.424)       1.83                        0.067         R   4.28     0.118      53.2
                                       C vs. T        3         1.267 (0.715,2.247)       0.81                        0.417         R   28.63    \< 0.001   93.0
  PC                                   CC vs. TT      3         0.962 (0.653,1.417)       0.20                        0.844         F   0.24     0.088      0.0
                                       TC vs. TT      3         1.678 (1.167,2.414)       2.79                        **0.005**     R   4.81     0.090      58.4
                                       CC+TC vs. TT   3         1.453 (1.172,1.802)       3.40                        **0.001**     F   2.72     0.257      26.4
                                       CC vs. TC+TT   3         0.717 (0.499,1.030)       1.80                        0.072         F   1.51     0.469      0.0
                                       C vs. T        3         1.158 (0.985,1.362)       1.77                        0.076         F   0.08     0.961      0.0
  Other                                CC vs. TT      6         1.203 (0.931,1.554)       1.41                        0.158         F   3.68     0.298      18.4
                                       TC vs. TT      6         0.919 (0.818,1.032)       1.43                        0.151         F   8.11     0.150      38.3
                                       CC+TC vs. TT   6         0.950 (0.851,1.061)       0.90                        0.367         F   9.90     0.078      49.5
                                       CC vs. TC+TT   6         1.227 (0.952,1.581)       1.58                        0.113         F   2.80     0.424      0.0
                                       C vs. T        6         0.986 (0.837,1.161)       0.17                        0.862         R   10.87    0.054      54.0

*OR, odds ratio; vs., versus; CI, confidence interval; P, p-value of Z-test for pooled OR; P~h~, p-value of heterogeneity test; PB, population-based; HB, hospital-based; F, fixed effect model; R, random effect model; ALL, acute lymphoblastic leukemia; BC, breast cancer; BLC, bladder cancer; CRC, colorectal cancer; CSCC, cervical squamous cell carcinoma; EC, endometrial cancer; ESCC, esophageal cancer; GC, gastric cancer; GBC, gallbladder cancer; HCC, hepatocellular carcinoma; LC, lung cancer; NPC, nasopharyngeal carcinoma; OC, ovarian cancer; OSCC, oral squamous cell cancer; PC, prostate cancer; RCC, renal cell cancer; SCCHN, cell carcinoma of head and neck. Bold values are significant to P \< 0.05*.

In the respiratory system, cancer risk was found to be significantly increased in the CC genetic model as compared with those in the TT and TC+TT (recessive) models (CC vs.TT: OR = 1.575, 95% CI = 1.268--1.955, *P* \< 0.001; CC vs. TC+TT: OR = 1.527, 95% CI = 1.232--1.892, *P* \< 0.001) (Figure [2](#F2){ref-type="fig"}), especially in lung cancer. We also found significantly increased cancer risk in all five genetic models of the digestive system (CC vs.TT: OR = 1.153, 95% CI = 1.027--1.295, *P* = 0.016; TC vs. TT: OR = 1.109, 95% CI = 1.046--1.176, *P* = 0.001; CC+TC vs. TT: OR = 1.112, 95% CI = 1.018--1.216, *P* = 0.019; CC vs. TC+TT: OR = 1.137, 95% CI = 1.016--1.272, *P* = 0.025; C vs. T: OR = 1.112, 95% CI = 1.025--1.206, *P* = 0.011; Figure [3](#F3){ref-type="fig"}), particularly in hepatocellular carcinoma. Significant association was observed between rs3746444 and increased cancer risk in three genetic models in the urinary system (TC vs. TT: OR = 1.307, 95% CI = 1.130--1.512, *P* \< 0.001; CC+TC vs. TT = 1.259, 95% CI = 1.097--1.446, *P* = 0.001; C vs. T: OR = 1.132, 95% CI = 1.014--1.264, *P* = 0.027; Figure [4](#F4){ref-type="fig"}), as well as for prostate cancer. Our results showed that rs3746444 could increase cancer risk of the gynecological system in the allelic model (C vs. T: OR = 1.169, 95% CI = 1.002--1.364, *P* = 0.047; Figure [5](#F5){ref-type="fig"}), particularly for cervical squamous cell carcinoma. However, studies on lymphatic and hematopoietic system cancers did not reveal any significant association between cancer risk and genetic models. In addition, no significant association between the five different genetic models and cancer risk in other types of cancers were observed.

![Forest plot of the OR and 95% CIs for association between microRNA-499 rs3746444 polymorphism and cancer risk of respiratory system in homozygote comparison model. OSCC, oral squamous cell cancer; LC, lung cancer; NPC, nasopharyngeal carcinoma.](fphys-09-00737-g0002){#F2}

![Forest plot of the OR and 95% CIs for association between microRNA-499 rs3746444 polymorphism and cancer risk of digestive system in allelic model. HCC, hepatocellular carcinoma; ESCC, esophageal cancer; CRC, colorectal cancer; GC, gastric cancer; GBC, gallbladder cancer.](fphys-09-00737-g0003){#F3}

![Forest plot of the OR and 95% CIs for association between microRNA-499 rs3746444 polymorphism and cancer risk of urinary system in allelic model. PC, prostate cancer; BLC, bladder cancer; RCC, renal cell cancer.](fphys-09-00737-g0004){#F4}

![Forest plot of the OR and 95% CIs for association between microRNA-499 rs3746444 polymorphism and cancer risk of gynecological system in allelic model. BC, breast cancer; CSCC, cervical squamous cell carcinoma; EC, endometrial cancer; OC, ovarian cancer.](fphys-09-00737-g0005){#F5}

We then performed subgroup analysis based on ethnicity, source of control, and HWE in controls. When results were stratified by ethnicity, significant association was found between miR-499 rs3746444 polymorphism and cancer risk in the Asians; (CC vs. TT: OR = 1.301, 95% CI = 1.180--1.434, *P* \< 0.001; TC vs. TT: OR = 1.123, 95% CI = 1.040--1.213, *P* = 0.003; CC+TC vs. TT: OR = 1.152, 95% CI = 1.065--1.247, *P* \< 0.001; CC vs. TC+TT: OR = 1.267, 95% CI = 1.151--1.394, *P* \< 0.001; C vs. T: OR = 1.136, 95% CI = 1.072--1.237, *P* \< 0.001) this association was absent in the Caucasians. When analysis was performed on source of control, the ORs were significant in four genetic models for the population-based control. At the same time, significant associations were observed for the hospital-based control in the homozygote comparison model and the recessive model. Following the removal of 21 studies whose genotypic distributions in controls were not in accordance with HWE, the results remained the same.

Sensitivity analysis
--------------------

Sensitivity analysis was used to estimate the contribution of each study to the pooled ORs. Our results showed that the total ORs were not significantly altered following removal of studies where the controls were not in accordance with HWE. This further supported the significant association between miR-499 rs3746444 and cancer risk.

Publication bias
----------------

In this meta-analysis, the potential effect of publication bias in literatures was estimated by funnel plots (Figure [6](#F6){ref-type="fig"}) and the Egger\'s test. Based on our analysis, no publication bias was found (*P* \> 0.05).

![Funnel plot analysis to detect publication bias for allelic model. **(A)** respiratory system; **(B)** digestive system; **(C)** urinary system; **(D)** gynecological system.](fphys-09-00737-g0006){#F6}

Discussion {#s4}
==========

The odds of getting cancer varies widely among different individuals. Many studies have discovered that miRNAs are strongly associated with tumorigenesis and can act as oncogenes or tumor suppressor genes that affect the initiation and development of tumors (Zhou et al., [@B77]). In recent years, the status of SNPs in microRNAs and their potential effects on cancer risk have been extensively studied. Though several studies and meta-analyses have been carried out to evaluate the association between miR-499 rs3746444 T \> C polymorphism and cancer risk, no conclusive findings have been obtained in different cancers. Hence, integrating and updating these results to explore the relationship further is important.

In this study, our results demonstrate significant associations between miR-499 rs3746444 polymorphism and cancer susceptibility for the first time, in five different genetic models from 65 case-control studies. Meta-analyses of all types of cancer risks by other groups have found either no association between the miR-499 polymorphism and cancer susceptibility or significant associations in one or two genetic models (Xu et al., [@B67]). Several meta-analyses have explored the association between the miR-499 rs3746444 polymorphism and cancer risk and it is difficult to judge if the analysis without studies departing from HWE would be more valid or not. An overall meta-analysis by Jiang et al. ([@B24]) demonstrated a borderline association (TC+CC vs. TT: OR = 1.15, *P* = 0.04). However, the association disappeared (TC+CC vs. TT: OR = 1.18, *P* = 0.21) when studies departing from HWE were excluded. In our study, after the exclusion of 21 studies wherein the genotypic distributions in controls were not in accordance with HWE, the results were still significant. Therefore, though there is still no consensus on whether or not to include studies that deviate from HWE, our results basically were not affected by such studies.

The most important feature of our study is that it is the first meta-analysis to explore the associations between miR-499 polymorphism and cancer susceptibility in different systems comprehensively. We found that microRNA-499 rs3746444 was significantly associated with an increased risk of cancer of the respiratory system in two genetic models, digestive system in all five genetic models, the urinary system in three genetic models, and gynecological system in an allelic model. To the best of our knowledge, no previous meta-analysis has explored this association in cancer of the respiratory system. We also found that miR-499 rs3746444 C allele might increase the risk of lung cancer in a homozygote comparison model. Previous studies have reported that rs3746444 was significantly associated with an increased risk of lung cancer and could contribute to a poor prognosis by modulating the expression of cancer-related genes leading to tumorigenesis and resistance to chemotherapy in lung cancer (Li D. et al., [@B29]). Our data differs from that of Li et al. ([@B30]), since their analysis which included 12 gastrointestinal cancer studies, demonstrated no association between miR-499 rs3746444 and gastrointestinal cancer. We included 33 gastrointestinal cancer studies in this meta-analysis. In our analysis, though the number of the studies evaluating the association between hepatocellular carcinoma and miR-499 was the largest, the results were inconsistent on account of the small sample sizes and different ethnic groups. MicroRNA-499 downregulates the expression of the ets1 proto-oncogene in HepG2 cells and plays a vital role in the pathogenesis of HCC (Wei et al., [@B63]). In addition, we found that miR-499 rs3746444 C allele can increase the risk of hepatocellular carcinoma in recessive and allelic models. Our findings from the allelic hepatocellular carcinoma model were consistent with those of Yu et al. ([@B70]). We also found that that rs3746444 could increase the risk of gynecological cancers in an allelic model. At the same time, miR-499 rs3746444 was associated with susceptibility to cervical squamous cell carcinoma. Consistent with the findings of Wang et al. ([@B61]), we also found a significant association between rs3746444 and increased risk for cancer of the urinary system in two genetic models, but not the allelic model. Our results also suggested a significant association between miR-499 rs3746444 and prostate cancer risk in the heterozygote comparison and dominant models. George et al. have shown that a heterozygous miR-499 genotype, confers an increased risk of developing prostate cancer in the North Indian population (George et al., [@B15]). Nikolic et al. found that rs3746444 qualifies for a genetic variant potentially associated with aggressive prostate cancer in the Serbian population (Nikolic et al., [@B39]). Classifying cancer into different systems provides a new perspective and an in-depth understanding of the association between the miR-499 polymorphism and cancer susceptibility.

As for subgroup analysis based on ethnicity, our results were consistent with those of other meta-analyses. We found an association between the miR-499 polymorphism and cancer risk in Asians, but not in Caucasians. Unlike the other analyses, we found an association among the five genetic models in the Asian population. Our results suggest that miR-499 rs3746444 is associated with susceptibility to cervical squamous cell carcinoma, lung cancer, prostate cancer, and hepatocellular carcinoma, but not other cancer types, indicating that rs3746444 may have different effects on different cancer types. Compared to the previous studies, the difference in results could also be due to a lack of articles on miR-499 polymorphism and cancer risk.

Although our study pooled a large number of cases and controls including 52456 individuals, limitations which might affect the objectivity of the results still exist. First, our studies included data from only Asians and Caucasians and none from the African population. Second, detailed and original patient information such as age, gender, lifestyle, family history, nutrient intake was lacking. Third, gene-gene and gene-environment interactions should have been taken into consideration, if the relevant information was available.

In conclusion, our meta-analysis found that miR-499 rs3746444 polymorphism is associated with the risk of cancer in five genetic models. MicroRNA-499 rs3746444 was found to be significantly associated with increased risk of cancer of the respiratory, digestive, urinary, and gynecological systems. The subgroup analysis by ethnicity showed a significant association with increased cancer risk in the Asian population. Our findings also suggest that the miR-499 rs3746444 C allele may increase the risk of cervical squamous cell carcinoma, lung cancer, prostate cancer, and hepatocellular carcinoma. Well-designed and large-scale studies are, therefore, necessary to further verify these findings.
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